Recent Updates
Recently added Catalysts

Liarozole

Phase 2

Ichthyosis, Lamellar | Small molecule | Other |GSK plc|Last Updated: Sep 26, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment98
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00282724Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar IchthyosisPHASE2 COMPLETED 98Jan 1, 2006Apr 1, 2007Sep 26, 201116 Belgium, Canada +7
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Efficacy: Investigator's Global Assessment
Secondary Endpoints
Overall Scaling Score
Severity scores of other symptoms
Quality of Life
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
LiarozoleDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range14 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Subjects of either sex aged 14 years or older. * Clinical diagnosis of lamellar ichthyosis * Women of childbearing potential should use appropriate contraception * Women of childbearing potential should have a negative pregnancy test at screening visit. * Subjects are, except ...

Countries:BelgiumCanadaDominican RepublicFranceGermanyItalyNetherlandsNorwaySweden
Unlock Eligibility Criteria